Literature DB >> 23868091

The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening.

Rebecca A Hubbard1, Eric Johnson, Raymond Hsia, Carolyn M Rutter.   

Abstract

BACKGROUND: Annual colorectal cancer screening with fecal occult blood test (FOBT) is a noninvasive alternative to screening colonoscopy once every 10 years. If false-positive FOBT results are common, then many patients selecting an FOBT regimen will be exposed to the same invasive testing as those selecting a colonoscopy regimen. The objective of this study was to estimate the probability of experiencing a false-positive after receiving annual FOBT screening for 10 years.
METHODS: Medical records for patients aged 50 to 79 years receiving FOBT screening with Hemoccult Sensa between 1997 and 2009 at Group Health of Washington State captured the date and results of each FOBT, along with subsequent colorectal cancer diagnoses. We used logistic regression to analyze associations between patient characteristics and odds of a positive FOBT with no invasive cancer diagnosis within 1 year (FOBT+, CRC-). We estimated the probability of receiving at least one FOBT+, CRC- result after 10 years of screening.
RESULTS: We observed 181,950 FOBTs from 94,637 individuals. Older patients, males, and non-White patients were significantly more likely to receive FOBT+, CRC- results (P < 0.001 for all risk factors). After 10 years of annual FOBT, 23.0% [95% confidence interval (CI), 18.2-27.0] will receive at least one FOBT+, CRC- result.
CONCLUSIONS: Most patients participating in annual FOBT screening for 10 years will not have a positive result, reinforcing the potential value of this regimen as a noninvasive alternative to colonoscopy. IMPACT: Annual stool-based screening is a screening alternative resulting in substantially fewer colonoscopies than once per decade colonoscopy. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23868091      PMCID: PMC3770276          DOI: 10.1158/1055-9965.EPI-13-0254

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  21 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Ascertainment of colonoscopy indication using administrative data.

Authors:  Deborah A Fisher; Janet M Grubber; John M Castor; Cynthia J Coffman
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

3.  Trends in colorectal cancer test use among vulnerable populations in the United States.

Authors:  Carrie N Klabunde; Kathleen A Cronin; Nancy Breen; William R Waldron; Anita H Ambs; Marion R Nadel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-08       Impact factor: 4.254

4.  Longitudinal adherence with fecal occult blood test screening in community practice.

Authors:  Joshua J Fenton; Joann G Elmore; Diana S M Buist; Robert J Reid; Daniel J Tancredi; Laura-Mae Baldwin
Journal:  Ann Fam Med       Date:  2010 Sep-Oct       Impact factor: 5.166

5.  Positive predictive value of fecal occult blood testing in persons taking warfarin.

Authors:  Edmund J Bini; Roshini C Rajapaksa; Elizabeth H Weinshel
Journal:  Am J Gastroenterol       Date:  2005-07       Impact factor: 10.864

6.  Randomised study of screening for colorectal cancer with faecal-occult-blood test.

Authors:  O Kronborg; C Fenger; J Olsen; O D Jørgensen; O Søndergaard
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

7.  A semiparametric censoring bias model for estimating the cumulative risk of a false-positive screening test under dependent censoring.

Authors:  Rebecca A Hubbard; Diana L Miglioretti
Journal:  Biometrics       Date:  2013-02-05       Impact factor: 2.571

8.  Patterns and predictors of colorectal cancer test use in the adult U.S. population.

Authors:  Laura C Seeff; Marion R Nadel; Carrie N Klabunde; Trevor Thompson; Jean A Shapiro; Sally W Vernon; Ralph J Coates
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860

9.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

10.  A comparison of fecal occult-blood tests for colorectal-cancer screening.

Authors:  J E Allison; I S Tekawa; L J Ransom; A L Adrain
Journal:  N Engl J Med       Date:  1996-01-18       Impact factor: 91.245

View more
  11 in total

1.  Implications of false-positive results for future cancer screenings.

Authors:  Glen B Taksler; Nancy L Keating; Michael B Rothberg
Journal:  Cancer       Date:  2018-04-23       Impact factor: 6.860

2.  Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study.

Authors:  Thomas G Cotter; Kelli N Burger; Mary E Devens; Julie A Simonson; Kari L Lowrie; Russell I Heigh; Douglas W Mahoney; David H Johnson; David A Ahlquist; John B Kisiel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12-20       Impact factor: 4.254

3.  Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates.

Authors:  Sarah A Nowak; Andrew M Parker
Journal:  Am J Public Health       Date:  2014-10-16       Impact factor: 9.308

Review 4.  Cancer Screening in Older Adults: Individualized Decision-Making and Communication Strategies.

Authors:  Ashwin A Kotwal; Louise C Walter
Journal:  Med Clin North Am       Date:  2020-09-16       Impact factor: 5.456

5.  Cancer Models and Real-world Data: Better Together.

Authors:  Jane J Kim; Anna Na Tosteson; Ann G Zauber; Brian L Sprague; Natasha K Stout; Oguzhan Alagoz; Amy Trentham-Dietz; Katrina Armstrong; Sandi L Pruitt; Carolyn M Rutter
Journal:  J Natl Cancer Inst       Date:  2015-11-03       Impact factor: 13.506

6.  Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?

Authors:  Anna Pellat; Jacques Deyra; Marie Husson; Robert Benamouzig; Romain Coriat; Stanislas Chaussade
Journal:  Therap Adv Gastroenterol       Date:  2021-05-07       Impact factor: 4.409

7.  The cumulative false-positive rate in colorectal cancer screening: a Markov analysis.

Authors:  Ulrike Haug; Veerle M H Coupé
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-05       Impact factor: 2.586

Review 8.  Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy.

Authors:  Derek W Ebner; John B Kisiel
Journal:  Curr Gastroenterol Rep       Date:  2020-06-03

9.  Effectiveness of Interventions to Increase Colorectal Cancer Screening Among American Indians and Alaska Natives.

Authors:  Donald Haverkamp; Kevin English; Jasmine Jacobs-Wingo; Amanda Tjemsland; David Espey
Journal:  Prev Chronic Dis       Date:  2020-07-16       Impact factor: 2.830

10.  Development of Surface-Enhanced Raman Scattering (SERS)-Based Surface-Corrugated Nanopillars for Biomolecular Detection of Colorectal Cancer.

Authors:  Kuan-Hung Chen; Meng-Ju Pan; Zoljargal Jargalsaikhan; Tseren-Onolt Ishdorj; Fan-Gang Tseng
Journal:  Biosensors (Basel)       Date:  2020-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.